跳至主要内容
临床试验/NCT00316459
NCT00316459已完成1 期

A Randomized, Double-Blind, Placebo and Moxifloxacin (Open-Label) Controlled, 4-Period, Crossover Study of the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2006年5月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
64
试验地点
1
主要终点
To assess the effect of ERB-041 after multiple oral doses on cardiac repolarization as assessed by the QTc interval

研究概览

简要总结

To assess the effect of ERB-041 after multiple oral doses on cardiac repolarization as assessed by the QTc interval.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and ECG.
  • Nonsmoker or smoker of fewer than 10 cigarettes (half a pack) per day as determined by history.

排除标准

  • A family history of long QT syndrome and/or cardiac death.
  • Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematological, neurological, or psychiatric disease.

结局指标

主要结局

To assess the effect of ERB-041 after multiple oral doses on cardiac repolarization as assessed by the QTc interval

次要结局

  • To characterize pharmacokinetic and pharmacodynamic relationships as it relates to QTc.

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验